Focal therapy is a novel treatment strategy in prostate cancer aiming to treat only the area of the gland harbouring clinically significant disease.
The overall objective is to maintain the oncological benefit of active treatment while minimising treatment-related morbidity. Leading centres are currently evaluating various minimally invasive technologies in a rigorous manner. Oncological and functional results in mid-term are encouraging with low rate of urinary incontinence and erectile dysfunction. However, the oncological outcome needs to be evaluated in the long-term in the light of the prolonged natural history of the disease.
Written by:
Valerio M, Benamran D, Tawadros T, Cerantola Y, Meuwly JY, Lutchmaya-Flick C, Lhermitte B, Wirth G, Iselin C, Jichlinski P. Are you the author?
Reference: Rev Med Suisse. 2014 Dec 3;10(453):2306-10.
PubMed Abstract
PMID: 25626246
Article in French.